# US 6,730,320 B2 · Tetracycline antibiotic product, use and formulation thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,320 B2
- Document ID: US6730320B2
- Status: Granted
- Kind: B2
- Application number: 10/028,590
- Filed: 2001-12-20
- Published: 2002-09-26
- Granted: 2004-05-04
- Earliest claimed: 2000-02-24
- Assignees: Advancis Pharmaceutical Corp.
- Inventors: Edward M. Rudnic; James D. Isbister; Donald J. Treacy, Jr.; Sandra E. Wassink
- Web page: https://patentgrep.com/patent/US6730320B2

## CPC

- A61K 9/2081: {with microcapsules or coated microparticles according to A61K9/50}
- A61K 9/5084: {Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs (tablets containing such a mixture A61K9/2077)}
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/4164: 1,3-Diazoles
- A61K 31/43: Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula [IMAGE cpc-sch-A61K-0952.gif], e.g. penicillins, penems
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 9/1635: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 9/5026: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

An antibiotic product, in particular a tetracycline, such as doxycycline, is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.

## Claims

### Claim 1

A once-a-day antibiotic product comprising: first, second, and third dosage forms; each of said dosage forms comprising a tetracycline and a pharmaceutically acceptable carrier; said first dosage form being an immediate release dosage form; said second and third dosage forms being delayed release dosage forms; wherein each of said first, second, and third dosage forms initiates release of the tetracycline at different times; wherein Cmax of the total tetracycline released from said product is achieved in less than about 12 hours from administration; and wherein said once-a-day product contains the total dosage of the tetracycline for a twenty-four hour period.

### Claim 2 (depends on 1)

The product of claim 1, wherein said tetracycline is doxycycline.

### Claim 3 (depends on 2)

The product of claim 2, wherein the Cmax for the product is reached no earlier than four hours after administration.

### Claim 4 (depends on 2)

The product of claim 2, wherein the doxycycline released from the first dosage form reaches a Cmax within from about 0.5 hours to about 2 hours after administration of the product.

### Claim 5 (depends on 2)

The product of claim 2, wherein the doxycycline released from the second dosage form reaches a Cmax in no more than about 4 hours after administration of the product.

### Claim 6 (depends on 2)

The product of claim 2, wherein the doxycycline released from the third dosage form reaches a Cmax within 8 hours after administration of the product.

### Claim 7 (depends on 2)

The product of claim 2, wherein the immediate release dosage form contains at least 20% and no more than 50% of the total dosage of doxycycline.

### Claim 8 (depends on 2)

The product of claim 2, wherein the product is an oral dosage form.

### Claim 9 (depends on 2)

The product of claim 2, wherein the doxycycline released from the second dosage form reaches a Cmax after Cmax is reached for the doxycycline released from the first dosage form.

### Claim 10 (depends on 2)

The product of claim 2, wherein the doxycycline released from the third dosage form reaches a Cmax after Cmax is reached for the doxycycline released from the second dosage form.

### Claim 11 (depends on 2)

The product of claim 2, further comprising a fourth dosage form, said fourth dosage form being a delayed release dosage form comprising doxycycline and a pharmaceutically acceptable carrier; and wherein doxycycline released from said fourth dosage form reaches a Cmax after Cmax is achieved for doxycycline released from each of said first, second, and third dosage forms.

### Claim 12 (depends on 11)

The product of claim 11, wherein the Cmax for the product is reached no earlier than four hours after administration.

### Claim 13 (depends on 11)

The product of claim 11, wherein the doxycycline released from the first dosage form reaches a Cmax within from about 0.5 hours to about 2 hours after administration of the product.

### Claim 14 (depends on 11)

The product of claim 11, wherein the doxycycline released from the second dosage form reaches a Cmax in no more than about 4 hours after administration of the product.

### Claim 15 (depends on 11)

The product of claim 11, wherein the doxycycline released from the third dosage form reaches a Cmax within 8 hours after administration of the product.

### Claim 16 (depends on 11)

The product of claim 11, wherein said second dosage form initiates release of doxycycline before said third dosage form, wherein said third dosage form initiates release of doxycycline before said fourth dosage form, wherein said second dosage form provides 20% to 35% by weight of the total doxycycline released by said second, third, and fourth dosage forms, wherein said third dosage form provides from 20% to 40% by weight of the total doxycycline released by said second, third, and fourth dosage forms, and wherein said fourth dosage form provides the remainder of the total doxycycline released by said second, third, and fourth dosage forms.

### Claim 17 (depends on 11)

The product of claim 11, wherein the product is an oral dosage form.

### Claim 18 (depends on 11)

The product of claim 11, wherein the doxycycline released from the second dosage form reaches a Cmax after Cmax is reached for the doxycycline released from the first dosage form.

### Claim 19 (depends on 11)

The product of claim 11, wherein the doxycycline released from the third dosage form reaches a Cmax after Cmax is reached for the doxycycline released from the second dosage form.

### Claim 20 (depends on 1)

A process for treating a bacterial infection in a host comprising:
administering to a host the product of claim 1, once-a-day.

### Claim 21 (depends on 2)

A process for treating a bacterial infection in a host comprising:
administering to a host the doxycycline product of claim 2, once-a-day.

### Claim 22 (depends on 3)

A process for treating a bacterial infection in a host comprising:
administering to a host the doxycycline product of claim 3, once-a-day.

### Claim 23 (depends on 4)

A process for treating a bacterial infection in a host comprising:
administering to a host the doxycycline product of claim 4, once-a-day.

### Claim 24 (depends on 5)

A process for treating a bacterial infection in a host comprising:
administering to a host the doxycycline product of claim 5, once-a-day.

### Claim 25 (depends on 6)

A process for treating a bacterial infection in a host comprising:
administering to a host the doxycycline product of claim 6, once-a-day.

### Claim 26 (depends on 7)

A process for treating a bacterial infection in a host comprising:
administering to a host the doxycycline product of claim 7, once-a-day.

### Claim 27 (depends on 8)

A process for treating a bacterial infection in a host comprising:
administering to a host the doxycycline product of claim 8, once-a-day.

### Claim 28 (depends on 9)

A process for treating a bacterial infection in a host comprising:
administering to a host the doxycycline product of claim 9, once-a-day.

### Claim 29 (depends on 10)

A process for treating a bacterial infection in a host comprising:
administering to a host the doxycycline product of claim 10, once-a-day.

### Claim 30 (depends on 11)

A process for treating a bacterial infection in a host comprising:
administering to a host the doxycycline product of claim 11, once-a-day.

### Claim 31 (depends on 12)

A process for treating a bacterial infection in a host comprising:
administering to a host the doxycycline product of claim 12, once-a-day.

### Claim 32 (depends on 13)

A process for treating a bacterial infection in a host comprising:
administering to a host the doxycycline product of claim 13, once-a-day.

### Claim 33 (depends on 14)

A process for treating a bacterial infection in a host comprising:
administering to a host the doxycycline product of claim 14, once-a-day.

### Claim 34 (depends on 15)

A process for treating a bacterial infection in a host comprising:
administering to a host the doxycycline product of claim 15, once-a-day.

### Claim 35 (depends on 16)

A process for treating a bacterial infection in a host comprising:
administering to a host the doxycycline product of claim 16, once-a-day.

### Claim 36 (depends on 17)

A process for treating a bacterial infection in a host comprising:
administering to a host the doxycycline product of claim 17, once-a-day.

### Claim 37 (depends on 18)

A process for treating a bacterial infection in a host comprising:
administering to a host the doxycycline product of claim 18, once-a-day.

### Claim 38 (depends on 19)

A process for treating a bacterial infection in a host comprising:
administering to a host the doxycycline product of claim 19, once-a-day.

### Claim 39 (depends on 2)

The product of claim 2, wherein the doxycycline is in the form of a salt.

### Claim 40 (depends on 39)

A process for treating a bacterial infection in a host comprising:
administering to a host the doxycycline product of claim 39, once-a-day.
